|
Market Closed -
Australian S.E.
07:10:28 28/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 181.91 AUD | +2.80% |
|
+2.02% | +5.36% |
| 09-22 | Csl Canada Expands Public Access to Andembry® Across Canada for the Prevention of Hereditary Angioedema Attacks | CI |
| 09-21 | Australian shares end flat as miners offset gains in banks | RE |
Company Valuation: CSL Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 89,299 | 89,052 | 95,184 | 76,024 | 38,015 | 59,515 | - | - |
| Change | - | -0.28% | 6.89% | -20.13% | -50% | 56.56% | - | - |
| Enterprise Value (EV) 1 | 88,520 | 99,731 | 105,710 | 85,005 | 47,398 | 68,693 | 68,386 | 67,902 |
| Change | - | 12.66% | 5.99% | -19.59% | -44.24% | 44.93% | -0.45% | -0.71% |
| P/E | 38.6x | 40.8x | 36.1x | 25.4x | -14.8x | 20.5x | 18.5x | 17.6x |
| PBR | 6.13x | 5.64x | 5.48x | 3.93x | 2.57x | 3.69x | 3.39x | 3.09x |
| PEG | - | -7.25x | 1.8x | 1.9x | 0x | -0x | 1.7x | 3.46x |
| Capitalization / Revenue | 8.45x | 6.69x | 6.43x | 4.89x | 2.41x | 3.77x | 3.65x | 3.5x |
| EV / Revenue | 8.38x | 7.49x | 7.14x | 5.46x | 3x | 4.36x | 4.19x | 3.99x |
| EV / EBITDA | 24.6x | 25.6x | 22.3x | 16.5x | 10.7x | 13.5x | 12.8x | 12.1x |
| EV / EBIT | 30.2x | 32.5x | 27.7x | 19x | 10.3x | 15.7x | 14.9x | 14.1x |
| EV / FCF | 57.1x | 72.6x | 55.2x | 29.1x | 16.5x | 22x | 23.3x | 21.9x |
| FCF Yield | 1.75% | 1.38% | 1.81% | 3.44% | 6.05% | 4.56% | 4.3% | 4.56% |
| Dividend per Share 2 | 2.22 | 2.36 | 2.64 | 2.92 | 2.92 | 3.002 | 3.191 | 3.42 |
| Rate of return | 1.2% | 1.28% | 1.34% | 1.86% | 3.68% | 2.42% | 2.57% | 2.75% |
| EPS 2 | 4.8 | 4.53 | 5.45 | 6.17 | -5.35 | 6.073 | 6.717 | 7.059 |
| Distribution rate | 46.3% | 52.1% | 48.4% | 47.3% | -54.6% | 49.4% | 47.5% | 48.5% |
| Net sales 1 | 10,562 | 13,310 | 14,800 | 15,558 | 15,797 | 15,767 | 16,320 | 17,016 |
| EBITDA 1 | 3,596 | 3,900 | 4,750 | 5,151 | 4,438 | 5,085 | 5,326 | 5,599 |
| EBIT 1 | 2,927 | 3,069 | 3,812 | 4,468 | 4,620 | 4,367 | 4,593 | 4,826 |
| Net income 1 | 2,255 | 2,194 | 2,642 | 3,002 | -2,579 | 2,823 | 3,159 | 3,360 |
| Net Debt 1 | -778.6 | 10,679 | 10,526 | 8,981 | 9,383 | 9,178 | 8,871 | 8,387 |
| Reference price 2 | 185.38 | 184.61 | 196.96 | 157.01 | 79.38 | 124.27 | 124.27 | 124.27 |
| Nbr of stocks (in thousands) | 481,706 | 482,372 | 483,253 | 484,212 | 478,912 | 478,912 | - | - |
| Announcement Date | 16/08/22 | 14/08/23 | 12/08/24 | 18/08/25 | 17/08/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.46x | 4.36x | 13.5x | 2.42% | 59.52B | |
| -23.72x | 36.06x | -23.41x | -.--% | 79.4B | |
| 17.96x | 4.21x | 9.93x | 0.5% | 78.69B | |
| 21.44x | 4.75x | 13.52x | 0.68% | 46.58B | |
| 33.28x | 11.32x | 21.7x | -.--% | 46.53B | |
| 37.12x | 3.69x | 13.85x | -.--% | 33.63B | |
| 55.29x | 3.51x | 27.23x | -.--% | 25.11B | |
| 63.28x | 7.06x | 42.21x | -.--% | 22.13B | |
| 22.86x | 4.91x | 12.8x | -.--% | 15.31B | |
| 56.21x | 34.68x | 51.72x | 0.17% | 12.82B | |
| Average | 30.42x | 11.46x | 18.30x | 0.38% | 41.97B | |
| Weighted average by Cap. | 20.02x | 12.13x | 10.26x | 0.52% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CSL Stock
- Valuation CSL Limited
Select your edition
All financial news and data tailored to specific country editions
